U
QuantRx Biomedical Corporation
QTXB
$0.0005
$0.0003150.00%
E
Sell
3/14/2023Downgrade
QuantRx Biomedical Corporation (QTXB) was downgraded to E+ from D on 03/14/2023.
QuantRx Biomedical Corporation (QTXB) was downgraded to E+ from D on 03/14/2023.
D
Sell
2/9/2023Upgraded
QuantRx Biomedical Corporation (QTXB) was upgraded to D from E+ on 02/09/2023.
QuantRx Biomedical Corporation (QTXB) was upgraded to D from E+ on 02/09/2023.
E
Sell
2/8/2023Downgrade
QuantRx Biomedical Corporation (QTXB) was downgraded to E+ from D on 02/08/2023.
QuantRx Biomedical Corporation (QTXB) was downgraded to E+ from D on 02/08/2023.
D
Sell
1/30/2023Upgraded
QuantRx Biomedical Corporation (QTXB) was upgraded to D from D- on 1/30/2023 due to a substantial increase in the total return index and volatility index.
QuantRx Biomedical Corporation (QTXB) was upgraded to D from D- on 1/30/2023 due to a substantial increase in the total return index and volatility index.
D
Sell
1/13/2023Downgrade
QuantRx Biomedical Corporation (QTXB) was downgraded to D- from D on 1/13/2023 due to a substantial decline in the total return index and volatility index.
QuantRx Biomedical Corporation (QTXB) was downgraded to D- from D on 1/13/2023 due to a substantial decline in the total return index and volatility index.
D
Sell
11/14/2022Upgraded
QuantRx Biomedical Corporation (QTXB) was upgraded to D from E+ on 11/14/2022 due to a substantial increase in the total return index and volatility index.
QuantRx Biomedical Corporation (QTXB) was upgraded to D from E+ on 11/14/2022 due to a substantial increase in the total return index and volatility index.
E
Sell
11/3/2022Downgrade
QuantRx Biomedical Corporation (QTXB) was downgraded to E+ from D- on 11/3/2022 due to a major decline in the total return index and volatility index.
QuantRx Biomedical Corporation (QTXB) was downgraded to E+ from D- on 11/3/2022 due to a major decline in the total return index and volatility index.
D
Sell
9/21/2022Downgrade
QuantRx Biomedical Corporation (QTXB) was downgraded to D- from D on 9/21/2022 due to a noticeable decline in the growth index and volatility index. EBIT declined 647.22% from -$3.6 to -$26.9, and earnings per share declined from -$0.0007 to -$0.001.
QuantRx Biomedical Corporation (QTXB) was downgraded to D- from D on 9/21/2022 due to a noticeable decline in the growth index and volatility index. EBIT declined 647.22% from -$3.6 to -$26.9, and earnings per share declined from -$0.0007 to -$0.001.
D
Sell
5/16/2022Upgraded
QuantRx Biomedical Corporation (QTXB) was upgraded to D from E+ on 05/16/2022.
QuantRx Biomedical Corporation (QTXB) was upgraded to D from E+ on 05/16/2022.
E
Sell
5/13/2022Downgrade
QuantRx Biomedical Corporation (QTXB) was downgraded to E+ from D on 5/13/2022 due to a decline in the total return index.
QuantRx Biomedical Corporation (QTXB) was downgraded to E+ from D on 5/13/2022 due to a decline in the total return index.
D
Sell
5/4/2022Upgraded
QuantRx Biomedical Corporation (QTXB) was upgraded to D from E+ on 05/04/2022.
QuantRx Biomedical Corporation (QTXB) was upgraded to D from E+ on 05/04/2022.
E
Sell
5/1/2022Downgrade
QuantRx Biomedical Corporation (QTXB) was downgraded to E+ from D on 05/01/2022.
QuantRx Biomedical Corporation (QTXB) was downgraded to E+ from D on 05/01/2022.
D
Sell
4/21/2022Upgraded
QuantRx Biomedical Corporation (QTXB) was upgraded to D from E+ on 04/21/2022.
QuantRx Biomedical Corporation (QTXB) was upgraded to D from E+ on 04/21/2022.
E
Sell
4/20/2022Downgrade
QuantRx Biomedical Corporation (QTXB) was downgraded to E+ from D on 4/20/2022 due to a decline in the solvency index. The quick ratio declined from 0.01 to 0.
QuantRx Biomedical Corporation (QTXB) was downgraded to E+ from D on 4/20/2022 due to a decline in the solvency index. The quick ratio declined from 0.01 to 0.
D
Sell
11/9/2021Upgraded
QuantRx Biomedical Corporation (QTXB) was upgraded to D from E+ on 11/09/2021.
QuantRx Biomedical Corporation (QTXB) was upgraded to D from E+ on 11/09/2021.
E
Sell
11/8/2021Downgrade
QuantRx Biomedical Corporation (QTXB) was downgraded to E+ from D on 11/08/2021.
QuantRx Biomedical Corporation (QTXB) was downgraded to E+ from D on 11/08/2021.
D
Sell
10/1/2021Upgraded
QuantRx Biomedical Corporation (QTXB) was upgraded to D from D- on 10/1/2021 due to an increase in the total return index.
QuantRx Biomedical Corporation (QTXB) was upgraded to D from D- on 10/1/2021 due to an increase in the total return index.
D
Sell
8/18/2021Downgrade
QuantRx Biomedical Corporation (QTXB) was downgraded to D- from D on 8/18/2021 due to a decline in the total return index, growth index and solvency index. EBIT declined 364% from -$5 to -$23.2, operating cash flow declined 200% from -$6.9 to -$20.7, and the quick ratio declined from 0.02 to 0.01.
QuantRx Biomedical Corporation (QTXB) was downgraded to D- from D on 8/18/2021 due to a decline in the total return index, growth index and solvency index. EBIT declined 364% from -$5 to -$23.2, operating cash flow declined 200% from -$6.9 to -$20.7, and the quick ratio declined from 0.02 to 0.01.
D
Sell
8/31/2020Upgraded
QuantRx Biomedical Corporation (QTXB) was upgraded to D from D- on 8/31/2020 due to a noticeable increase in the total return index.
QuantRx Biomedical Corporation (QTXB) was upgraded to D from D- on 8/31/2020 due to a noticeable increase in the total return index.
D
Sell
8/14/2020Downgrade
QuantRx Biomedical Corporation (QTXB) was downgraded to D- from D on 8/14/2020 due to a substantial decline in the valuation index, growth index and solvency index. Earnings per share declined from -$0.0006 to -$0.001, EBIT declined 64.94% from -$15.4 to -$25.4, and operating cash flow declined 55.43% from -$18.4 to -$28.6.
QuantRx Biomedical Corporation (QTXB) was downgraded to D- from D on 8/14/2020 due to a substantial decline in the valuation index, growth index and solvency index. Earnings per share declined from -$0.0006 to -$0.001, EBIT declined 64.94% from -$15.4 to -$25.4, and operating cash flow declined 55.43% from -$18.4 to -$28.6.
D
Sell
5/21/2020Upgraded
QuantRx Biomedical Corporation (QTXB) was upgraded to D from D- on 5/21/2020 due to a major increase in the growth index and volatility index. Earnings per share increased from -$0.004 to -$0.0006, EBIT increased 57.22% from -$36 to -$15.4, and operating cash flow increased 25.2% from -$24.6 to -$18.4.
QuantRx Biomedical Corporation (QTXB) was upgraded to D from D- on 5/21/2020 due to a major increase in the growth index and volatility index. Earnings per share increased from -$0.004 to -$0.0006, EBIT increased 57.22% from -$36 to -$15.4, and operating cash flow increased 25.2% from -$24.6 to -$18.4.
D
Sell
1/24/2020Downgrade
QuantRx Biomedical Corporation (QTXB) was downgraded to D- from D on 1/24/2020 due to a decline in the volatility index and total return index.
QuantRx Biomedical Corporation (QTXB) was downgraded to D- from D on 1/24/2020 due to a decline in the volatility index and total return index.
D
Sell
1/9/2020Upgraded
QuantRx Biomedical Corporation (QTXB) was upgraded to D from D- on 1/9/2020 due to a large increase in the total return index, growth index and volatility index. Operating cash flow increased 42.82% from -$80.8 to -$46.2, and EBIT increased 27.35% from -$61.8 to -$44.9.
QuantRx Biomedical Corporation (QTXB) was upgraded to D from D- on 1/9/2020 due to a large increase in the total return index, growth index and volatility index. Operating cash flow increased 42.82% from -$80.8 to -$46.2, and EBIT increased 27.35% from -$61.8 to -$44.9.
D
Sell
5/15/2019Upgraded
QuantRx Biomedical Corporation (QTXB) was upgraded to D- from E+ on 5/15/2019 due to an increase in the volatility index.
QuantRx Biomedical Corporation (QTXB) was upgraded to D- from E+ on 5/15/2019 due to an increase in the volatility index.
E
Sell
4/18/2019Downgrade
QuantRx Biomedical Corporation (QTXB) was downgraded to E+ from D on 4/18/2019 due to a significant decline in the efficiency index, growth index and total return index. Earnings per share declined from $0.0003 to -$0.0065, net income declined 2,255.46% from $23.8 to -$513, and operating cash flow declined 355.38% from -$19.5 to -$88.8.
QuantRx Biomedical Corporation (QTXB) was downgraded to E+ from D on 4/18/2019 due to a significant decline in the efficiency index, growth index and total return index. Earnings per share declined from $0.0003 to -$0.0065, net income declined 2,255.46% from $23.8 to -$513, and operating cash flow declined 355.38% from -$19.5 to -$88.8.
D
Sell
1/10/2019Downgrade
QuantRx Biomedical Corporation (QTXB) was downgraded to D from D+ on 1/10/2019 due to a significant decline in the valuation index, total return index and volatility index.
QuantRx Biomedical Corporation (QTXB) was downgraded to D from D+ on 1/10/2019 due to a significant decline in the valuation index, total return index and volatility index.
D
Sell
4/19/2018Upgraded
QuantRx Biomedical Corporation (QTXB) was upgraded to D+ from D on 4/19/2018 due to a significant increase in the valuation index, efficiency index and volatility index. Total capital increased 6,065.98% from $19.4 to $1.2M, and net income increased 1,788.84% from -$66.3 to $1.12M.
QuantRx Biomedical Corporation (QTXB) was upgraded to D+ from D on 4/19/2018 due to a significant increase in the valuation index, efficiency index and volatility index. Total capital increased 6,065.98% from $19.4 to $1.2M, and net income increased 1,788.84% from -$66.3 to $1.12M.
D
Sell
1/26/2018Upgraded
QuantRx Biomedical Corporation (QTXB) was upgraded to D from D- on 1/26/2018 due to a large increase in the total return index and volatility index.
QuantRx Biomedical Corporation (QTXB) was upgraded to D from D- on 1/26/2018 due to a large increase in the total return index and volatility index.
D
Sell
11/20/2017Downgrade
QuantRx Biomedical Corporation (QTXB) was downgraded to D- from D on 11/20/2017 due to a decline in the total return index and volatility index.
QuantRx Biomedical Corporation (QTXB) was downgraded to D- from D on 11/20/2017 due to a decline in the total return index and volatility index.
D
Sell
8/23/2017Upgraded
QuantRx Biomedical Corporation (QTXB) was upgraded to D from D- on 8/23/2017 due to a substantial increase in the valuation index, growth index and efficiency index. Operating cash flow increased 32.91% from -$39.2 to -$26.3, EBIT increased 4.11% from -$36.5 to -$35, and net income increased 1.19% from -$92.7 to -$91.6.
QuantRx Biomedical Corporation (QTXB) was upgraded to D from D- on 8/23/2017 due to a substantial increase in the valuation index, growth index and efficiency index. Operating cash flow increased 32.91% from -$39.2 to -$26.3, EBIT increased 4.11% from -$36.5 to -$35, and net income increased 1.19% from -$92.7 to -$91.6.
D
Sell
8/18/2016Downgrade
QuantRx Biomedical Corporation (QTXB) was downgraded to D- from D on 8/18/2016 due to a large decline in the growth index, efficiency index and volatility index. EBIT declined 101.13% from -$26.6 to -$53.5, earnings per share declined from -$0.001 to -$0.0016, and net income declined 47.95% from -$73.2 to -$108.3.
QuantRx Biomedical Corporation (QTXB) was downgraded to D- from D on 8/18/2016 due to a large decline in the growth index, efficiency index and volatility index. EBIT declined 101.13% from -$26.6 to -$53.5, earnings per share declined from -$0.001 to -$0.0016, and net income declined 47.95% from -$73.2 to -$108.3.
D
Sell
5/20/2016Upgraded
QuantRx Biomedical Corporation (QTXB) was upgraded to D from D- on 5/20/2016 due to a noticeable increase in the efficiency index, volatility index and growth index. EBIT increased 62.8% from -$71.5 to -$26.6, earnings per share increased from -$0.0013 to -$0.001, and net income increased 19.29% from -$90.7 to -$73.2.
QuantRx Biomedical Corporation (QTXB) was upgraded to D from D- on 5/20/2016 due to a noticeable increase in the efficiency index, volatility index and growth index. EBIT increased 62.8% from -$71.5 to -$26.6, earnings per share increased from -$0.0013 to -$0.001, and net income increased 19.29% from -$90.7 to -$73.2.
D
Sell
4/22/2016Downgrade
QuantRx Biomedical Corporation (QTXB) was downgraded to D- from D on 4/22/2016 due to a noticeable decline in the efficiency index and total return index.
QuantRx Biomedical Corporation (QTXB) was downgraded to D- from D on 4/22/2016 due to a noticeable decline in the efficiency index and total return index.
D
Sell
4/14/2016Downgrade
QuantRx Biomedical Corporation (QTXB) was downgraded to D from D+ on 4/14/2016 due to a significant decline in the efficiency index, volatility index and solvency index. The quick ratio declined from 0.05 to 0.03, and total capital declined 25.51% from -$64.3 to -$80.7.
QuantRx Biomedical Corporation (QTXB) was downgraded to D from D+ on 4/14/2016 due to a significant decline in the efficiency index, volatility index and solvency index. The quick ratio declined from 0.05 to 0.03, and total capital declined 25.51% from -$64.3 to -$80.7.
D
Sell
4/8/2016Upgraded
QuantRx Biomedical Corporation (QTXB) was upgraded to D+ from D on 4/8/2016 due to an increase in the volatility index and total return index.
QuantRx Biomedical Corporation (QTXB) was upgraded to D+ from D on 4/8/2016 due to an increase in the volatility index and total return index.
D
Sell
3/11/2016Downgrade
QuantRx Biomedical Corporation (QTXB) was downgraded to D from C- on 3/11/2016 due to a substantial decline in the volatility index, total return index and solvency index.
QuantRx Biomedical Corporation (QTXB) was downgraded to D from C- on 3/11/2016 due to a substantial decline in the volatility index, total return index and solvency index.
C
Hold
11/18/2015Upgraded
QuantRx Biomedical Corporation (QTXB) was upgraded to C- from D+ on 11/18/2015 due to a significant increase in the efficiency index. Net income increased 102.58% from -$54.2 to -$109.8, and total capital increased 19.29% from -$53.9 to -$64.3.
QuantRx Biomedical Corporation (QTXB) was upgraded to C- from D+ on 11/18/2015 due to a significant increase in the efficiency index. Net income increased 102.58% from -$54.2 to -$109.8, and total capital increased 19.29% from -$53.9 to -$64.3.
D
Sell
8/24/2015Downgrade
QuantRx Biomedical Corporation (QTXB) was downgraded to D+ from C on 8/24/2015 due to a significant decline in the efficiency index, total return index and volatility index. Net income declined 74.55% from -$213 to -$54.2, and total capital declined 27.55% from -$74.4 to -$53.9.
QuantRx Biomedical Corporation (QTXB) was downgraded to D+ from C on 8/24/2015 due to a significant decline in the efficiency index, total return index and volatility index. Net income declined 74.55% from -$213 to -$54.2, and total capital declined 27.55% from -$74.4 to -$53.9.
C
Hold
7/23/2015Upgraded
QuantRx Biomedical Corporation (QTXB) was upgraded to C from C- on 7/23/2015 due to an increase in the growth index. EBIT increased 33.13% from -$130.1 to -$173.2, and operating cash flow increased 0.15% from -$65 to -$65.1.
QuantRx Biomedical Corporation (QTXB) was upgraded to C from C- on 7/23/2015 due to an increase in the growth index. EBIT increased 33.13% from -$130.1 to -$173.2, and operating cash flow increased 0.15% from -$65 to -$65.1.
C
Hold
4/16/2015Upgraded
QuantRx Biomedical Corporation (QTXB) was upgraded to C- from D+ on 4/16/2015 due to a significant increase in the efficiency index, volatility index and solvency index. Net income increased 42.55% from -$157.7 to -$224.8, and debt to equity declined from -0.96 to -0.87.
QuantRx Biomedical Corporation (QTXB) was upgraded to C- from D+ on 4/16/2015 due to a significant increase in the efficiency index, volatility index and solvency index. Net income increased 42.55% from -$157.7 to -$224.8, and debt to equity declined from -0.96 to -0.87.
D
Sell
3/19/2015Upgraded
QuantRx Biomedical Corporation (QTXB) was upgraded to D+ from D on 3/19/2015 due to an increase in the volatility index.
QuantRx Biomedical Corporation (QTXB) was upgraded to D+ from D on 3/19/2015 due to an increase in the volatility index.
D
Sell
3/4/2015Downgrade
QuantRx Biomedical Corporation (QTXB) was downgraded to D from D+ on 3/4/2015 due to a significant decline in the volatility index, total return index and efficiency index. Total capital declined 606.06% from -$23.1 to $116.9, and net income declined 39.37% from -$260.1 to -$157.7.
QuantRx Biomedical Corporation (QTXB) was downgraded to D from D+ on 3/4/2015 due to a significant decline in the volatility index, total return index and efficiency index. Total capital declined 606.06% from -$23.1 to $116.9, and net income declined 39.37% from -$260.1 to -$157.7.
D
Sell
8/21/2014Downgrade
QuantRx Biomedical Corporation (QTXB) was downgraded to D+ from C- on 8/21/2014 due to a significant decline in the growth index.
QuantRx Biomedical Corporation (QTXB) was downgraded to D+ from C- on 8/21/2014 due to a significant decline in the growth index.
C
Hold
2/28/2014Downgrade
QuantRx Biomedical Corporation (QTXB) was downgraded to C- from C on 2/28/2014 due to a significant decline in efficiency.
QuantRx Biomedical Corporation (QTXB) was downgraded to C- from C on 2/28/2014 due to a significant decline in efficiency.
OTC PK
12/03/2024 11:00AM Eastern
Quotes delayed
